期刊文献+

胃病患者幽门螺旋杆菌感染状况及药物敏感试验分析 被引量:3

下载PDF
导出
摘要 目的探讨常见胃病的幽门螺旋杆菌(HP)感染情况及其HP感染患者药物敏感分析。方法取1038例胃病患者(浅表性胃炎695例,萎缩性胃炎20例,消化性溃疡274例,残胃炎24例,胃癌25例)胃黏膜活组织行采用HP培养及鉴定,对HP菌株采用抗菌药物药敏试纸片琼脂扩散法作药物敏感试验。结果1038例患者中有328例感染HP,胃癌、消化性溃疡、残胃炎、慢性胃炎HP阳性率分别为44.0%、40.5%、33.3%、27.7%。328例HP阳性患者对左氧氟沙星、庆大霉素、克拉霉素、呋喃唑酮及甲硝脞耐药率分别为2.1%、2.7%、26.8%、26.5%、98.5%。结论HP感染是多种胃病的致病因素,对HP感染患者首选左氧氟沙星、庆大霉素治疗,呋喃唑酮与克拉霉素不作首选,甲硝唑普遍耐药,不宜应用。
出处 《现代实用医学》 2009年第3期237-237,240,共2页 Modern Practical Medicine
  • 相关文献

参考文献6

  • 1Heicobacter and Cancer Collaborative Group. Gastric cancer and Helibacter pylori a combined analysis of 12 case-control studies nested with in prospective cohorts[J]. Gut, 2001, 49(3): 347-353.
  • 2成虹,胡伏莲.北京地区幽门螺杆菌耐药情况及其变化趋势[J].中华医学杂志,2005,85(39):2754-2757. 被引量:176
  • 3Megraud F. H pylori antibiotic resistance :prevalence,importance and advances in testing[J]. Gut. 2004, 53(9): 1374-1384.
  • 4Boyanova L, Gergova G, Nikolov R, et al .Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between sus ceptibility testing methods[J]. Diagn Microbiol Infect Dis. 2008, 60(4): 409-415.
  • 5Ndip RN, Malange Takang AE, Ojongokpoko JE, et al. Helicobacter pylori isolates recovered from gastric biopsies of patients with gastro-duodenal pathologies in Cameroon: current status of antibiogram[J]. Trop Med Int Health, 2008, 13 (6): 848-54.
  • 6曹春宇,金海,汤武亨,单友娟,李松财.舟山群岛地区幽门螺杆菌耐药情况临床研究[J].实用医学杂志,2008,24(6):967-968. 被引量:7

二级参考文献37

  • 1成虹,胡伏莲.北京地区幽门螺杆菌耐药情况及其变化趋势[J].中华医学杂志,2005,85(39):2754-2757. 被引量:176
  • 2Van der Hulst RW, Rauws EA, Koycu B, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology, 1997, 113: 1082-1086.
  • 3Malfertheiner P, Bayerdorffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther, 1999, 13: 703-712.
  • 4Bermejo F, Bioxeda D, Gisbert JP, et al. Effects of Helicobacter pylori after eradication on the recurrence of gastric ulcer during a 12-month follow up. Med Clin (Barc), 2000, 115: 201-204.
  • 5International Agency for Research on Cancer. Schistosomes, live flukes and Helicobacter pylori. LARC monographs on the evaluation on carcinogenic risks to humans. Vo161. Lyon: LARC, 1994.
  • 6Wotherspoon AC, Ortiz-Hidgo C, Falzon MR. Helicobacter pylori - associated gastritis and primary B - cdll gastric lymphoma. Lancet, 1991, 338: 1175-1176.
  • 7Eide S, Stolte M, Fisher, et al. Helicobacter pylori gastritis non - Hodgkin's lymphoma. J Ckin Pathol, 1994, 47: 436-439.
  • 8Wotherspoon AC, Dogliani C, Diss TC, et al. Regression of primary low grade B - cell gastric lymphoma of mucosa - associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 1993, 342: 4575-4577.
  • 9Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter, 2002, 7: 306-309.
  • 10Boyanova L, Koumanova R, Gergova G, et al. Prevalence of resistant Helicobacter pylori isolates in Bulgarian children. J Med Microbiol, 2002, 51: 786-790.

共引文献180

同被引文献33

  • 1王晶桐,刘玉兰.以耐信、呋喃唑酮为核心的四联疗法治疗一线、二线根治失败的幽门螺杆菌感染[J].胃肠病学和肝病学杂志,2006,15(5):519-521. 被引量:8
  • 2徐跃荣,汤迪军,卢放根.胃三联与胃二联疗法治疗幽门螺旋杆菌的临床研究[J].当代医师,1997,2(3):49-50. 被引量:1
  • 3Bago P, Vcev A, Tomic M, et al. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial[J]:Wien Klin Wochenschr,2007,119( 11 - 12) :372- 378.
  • 4Nista EC, Candelli M, Zocco MA, et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection[J]. Aliment Pharmacol Ther,2005,21 (10):1241-1247.
  • 5Miehlke S, Schneider-Brachert W, Kirsch C, et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin[J].Helicobacter,2008,13( 1):69-74.
  • 6Giannini EG, Bilardi C, Dulbecco P, et al. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication[J].Aliment Pharmacol Ther,2006,23(2):281-287.
  • 7Ruiz Gomez FA, Sanchez Serrano FJ, Martinez Egea A, et al. Intravenous 3-day ttelicobacter pylori eradication therapy is highly effective in patients with bleeding peptic ulcer [J].Gastroenterol Hepatol,2002,25 (6):383-386.
  • 8Sheu BS, Yang HB, Wang YL, et al. Stool antigen assay to screen H. pylori infection and to assess the success of 3-Day and 7-Day eradication therapy in the patients with partial gastrectomy[J].Helicobacter,2002,7 (3):199-204.
  • 9万国兰.消化性溃疡的药物治疗及进展[J].中国医药导报,2007,4(09X):5-6. 被引量:38
  • 10魏红,杨桂彬,胡伏莲,牟方宏,崔梅花.泮托拉唑四联5d疗法与7d疗法随机对照研究[J].世界华人消化杂志,2007,15(30):3241-3244. 被引量:2

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部